| Title | Suppression of testosterone levels by the chronic administration of the D-TRP6 Gn-RH analogue (decapeptyl/arvekap) in patients with advanced prostate carcinoma | |
| Authors | E. Venaki², V. Athanasiou², I. Diamantopoulos², P. Kehayas² and G. Tolis¹,²
1. University of Athens. 2. Hippokrateion Hospital, Divisions of Endocrinology and Urology, Athens, 115 27, Greece |
|
| Citation | Venaki, E., Athanasiou, V., Diamantopoulos, I., Kehayas, P., Tolis, G.: Suppression of testosterone levels by the chronic administration of the D-TRP6 Gn-RH analogue (decapeptyl/arvekap) in patients with advanced prostate carcinoma , Epitheorese Klin. Farmakol. Farmakokinet. 6(3): 134-136 (1992) | |
| Publication Date | Received for publication: 12 November 1992
Accepted for publication: 17 November 1992 |
|
| Full Text Language | English | |
| Order – Buy | Ηλεκτρονική Μορφή: pdf (10 €) – Digital Type: pdf (10 €)
pharmakonpress[at]pharmakonpress[.]gr |
|
| Keywords | Prostate cancer, testosterone, Gn-RH analogue. | |
| Other Terms | review article | |
| Summary | Administration of gonadotropin releasing hormone agonistic analogs (GnRH-a) initially stimulate and subsequently suppress testosterone production mainly via a pituitary gonadotrope suppression. Androgen dependent prostatic cancer is benefited by orchiectomy, estrogens and GnRH-a administered chronically. Our study addressed the question of whether gonadal suppression is maintained in prostatic cancer patients treated with a D-TRP6 GnRH-a for up to 9 years. Data for up to 2 years from another center and ours for up to 9 years documented that monthly injection of this analog indeed achieved long-lasting testicular suppression with testosterone levels similar to that of orchiectomy. | |
| References | 1. Borgman, V. et al.: Sustained suppression of testosterone production by the luteinizing-hormone, releasing hormone agonist Buserelin in patients with advanced prostate carcinoma: a new therapeutic approach. Lancet 1: 1097 (1982)
2. Tolis, G., Ackman, D. et al.: Tumor growth inhibition in patients with prostatic carcinoma treated with luteinizing hormone-releasing hormone agonists. P.N.A.S., 79: 1658- 1662(1982) 3. Koutsilieris M. and Tolis G.: Gonadotropin-releasing hormone agonistic analogues in the treatment of advanced prostatic cancer. The Prostate 4: 569 (1983) 4. Iversen, P.: Is there a case for total andogen blochade? EORTC Genitourinary Group Monograph 8: Treatment of Prostatic Cancer-Facts and Controversies, p.p. 109-115, Willey-Liss, Inc., 1990 |
|
| Relative Papers |
Online ISSN 1011-6575
Άρθρα Δημοσιευμένα σε αυτό το Περιοδικό Καταχωρούνται στα:
- Chemical Abstracts
- Elsevier’s Bibliographic Databases: Scopus, EMBASE, EMBiology, Elsevier BIOBASE SCImago Journal and Country Rank Factor
Articles published in this Journal are Indexed or Abstracted in: • Chemical Abstracts • Elsevier’s Bibliographic Databases: Scopus, EMBASE, EMBiology, Elsevier BIOBASE SCImago Journal and Country Rank Factor
Συντακτικη Επιτροπή-Editorial Board
| ΕΤΗΣΙΑ ΣΥΝΔΡΟΜΗ 1992 – ANNUAL SUBSCRIPTION 1992 | |
| Γλώσσα Πλήρους Κειμένου – Full Text Language | Αγγλικά – English |
| Παραγγελία – Αγορά – Order – Buy | Ηλεκτρονική Μορφή: pdf (70 €) – Digital Type: pdf (70 €)
pharmakonpress[at]pharmakonpress[.]gr |
| Έντυπη Μορφή (70 € + έξοδα αποστολής) – Printed Type (70 € + shipping)
pharmakonpress[at]pharmakonpress[.]gr |
|